TY - JOUR
TI - Acute triiodothyronine treatment and red blood cell sedimentation rate (ESR) in critically ill COVID-19 patients: A novel association?
AU - Pantos, C.
AU - Apostolaki, V.
AU - Kokkinos, L.
AU - Trikas, A.
AU - Mourouzis, I.
JO - Clinical Hemorheology and Microcirculation
PY - 2021
VL - 79
TODO - 3
SP - 485-488
PB - NLM (Medline)
SN - 1386-0291, 1875-8622
TODO - 10.3233/CH-211215
TODO - liothyronine, critical illness;  erythrocyte;  erythrocyte sedimentation rate;  human;  sepsis;  septic shock, Blood Sedimentation;  COVID-19;  Critical Illness;  Erythrocytes;  Humans;  SARS-CoV-2;  Sepsis;  Shock, Septic;  Triiodothyronine
TODO - Sepsis and septic shock result in impaired microcirculation and red blood cell rheology which lead to tissue hypoxia and multi-organ failure. Early administration of triiodothyronine prevents tissue hypoxia in experimental sepsis. In this context, a clinical trial was initiated to test the efficacy of acute triiodothyronine administration to combat tissue hypoxia in critically ill COVID19 patients. Here, we provide preliminary data from interim analysis of this study showing a novel acute effect of triiodothyronine on erythrocyte sedimentation rate which may have an important therapeutic impact on red blood cell rheology and tissue hypoxia in sepsis and particular in COVID19 critical illness.Trial registration: ClinicalTrials.gov, NCT04348513. Registered 16 April 2020, https://clinicaltrials.gov/ct2/show/NCT04348513.
ER -